



6643R2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	§	
James B. Camden, et al.	§	Examiner: C. Delacroix-Muirheid
	§	
Serial No.: 09/676,034	§	Group Art Unit: 1614
	§	
Filed: September 29, 2000	§	Express Mail No.: EL576204413US
	§	
For: Compounds and Methods for Use	§	Customer No. 030113
Thereof in the Treatment of Cancer	§	
or Viral Infections	§	

6/a
Harman
12/11/01

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Sir:

AMENDMENT; AND RESPONSE TO OFFICE ACTION
MAILED SEPTEMBER 14, 2001

The present paper is submitted as a complete response to the Official Action mailed September 14, 2001 having a shortened statutory period of response of three months, to and including December 14, 2001. The present paper is timely filed since this paper is being filed prior to or on the three-month date; however, should an extension of time be required, this paper is such a request. Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for the filing of the present document, the Commissioner is hereby authorized to deduct said fees from Procter & Gamble Deposit Account No. 16-2480.

Please amend the above-identified patent application as indicated below.

AMENDMENT

In the Specification:

At page 13, Table 2 is amended, as indicated below and in the marked up version included with this response as Attachment A:

Table 2

Cpd. No.	R ₁	R ₂	LogP
2-1	-CH ₂ CH ₂ CH ₂ N(CH ₂ CH ₃) ₂	H	1.098
2-2	-CH ₂ CH ₂ -morpholino	H	0.018
2-3	-CH(CH ₃)CH ₂ CH ₃	H	1.606
2-4	-CH ₂ -(2-tetrahydrofuryl)	H	0.613
2-5	-CH ₂ CH ₂ CH(CH ₃) ₂	H	1.920
2-6	-CH(CH ₃)CH ₂ CH(CH ₃) ₂	H	2.333
2-7	-CH ₂ CH ₂ C(CH ₃) ₃	H	2.353
2-8	-CH ₂ CH(CH ₃)CH ₂ CH ₃	H	1.992
2-9	-CH(CH ₂ CH ₃) ₂	H	2.075
2-10	-CH ₂ CH ₂ CH ₂ N(CH ₃) ₂	H	0.413
2-11	-CH ₂ CH ₂ OCH ₃	H	0.217
2-12	-NH-Ph	H	1.737
2-13	-Ph(2-OH)	H	1.779
2-14	-CH ₂ CH ₂ N(CH ₃) ₂	H	0.361
2-15	-Ph(3-OCH ₃ -4-OCH ₃ -5-OCH ₃)	H	1.305
2-16	cyclohexyl	CH ₃	2.213
2-17	-CH ₂ CH ₂ CH ₂ CH ₃	CH ₃	1.836
2-18	-CH ₂ CH ₂ CH ₃	CH ₂ CH ₂ CH ₃	2.250

At page 14, Table 3 is amended, as indicated below and in the marked up version included with this response as Attachment A:

Table 3

Cpd. No.	R ₁	Log P
3-1	-CH ₂ CH ₂ CH ₂ CH ₂ Cl	2.239
3-2	-CH ₂ CH ₂ OCH ₂ CH ₂ Cl	1.571
3-3	-CH ₂ CH=CH ₂	1.772
3-4	-(CH ₂ CH ₂ O) ₂ CH ₂ CH ₃	1.045
3-5	-CH ₂ CH ₂ OCH ₂ CH ₂ OH	0.424
3-6	-CH ₂ CH ₂ CH=CH ₂	2.024
3-7	-CH ₂ Ph	2.808
3-8	-CH ₂ CH ₂ N(CH ₃) ₂	1.011
3-9	-CH ₂ CH ₂ CH ₂ Cl	1.788
3-10	-CH ₂ CH=CHCH ₂ OH	1.121
3-11	-CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ OH	1.488
3-12	-CH(CH ₂ Cl) ₂	2.510
3-13	-CH ₂ CH(CH ₃)CH ₂ C(CH ₃) ₃	3.802
3-14	-CH ₂ CF ₂ CF ₃	2.841
3-15	-CH(CH ₂ F) ₂	1.423
3-16	-CH(CH ₃)(cyclopropyl)	2.155
3-17	-CH ₂ CH ₂ F	0.542
3-18	-CH(CH ₂ Br) ₂	2.636
3-19	-CH ₂ CH(CH ₃)CH ₂ CH ₃	2.256
3-20	-CH ₂ CH ₂ CH(CH ₃)CH ₂ C(CH ₃) ₃	4.126
3-21	-CH ₂ CH ₂ CH(CH ₃)CH ₂ CH ₂ CH=C(CH ₃) ₂	4.048

At page 16, the second paragraph, starting at line 10, is amended, as indicated below and in the marked up version included with this response as Attachment A:

DNA-interactive agents include alkylating agents, *e.g.*, cisplatin, cyclophosphamide, and altretamine; DNA strand-breakage agents, such as bleomycin; intercalating topoisomerase II inhibitors, *e.g.*, dactinomycin and doxorubicin; nonintercalating topoisomerase II inhibitors, such as etoposide and teniposide; and the DNA minor groove binder plicamycin, for example.

At page 17, the paragraph beginning at line 29 is amended as indicated below:

A listing of currently available chemotherapeutic agents according to class, and including diseases for which the agents are indicated, is provided as Table 3A.